On November 3, 2026 Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA therapeutics, reported two presentations at the 2026 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place November 4-8 in Phoenix: an oral presentation featuring updated clinical data from its STX-001 program and a trial-in-progress poster on the design of ASCENT-1, the company’s Phase I trial of its flagship clinical program STX-003.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
STX-001: Durable, systemic responses in advanced melanoma
Georgina Long, AO, PhD, MBBS (Hons), FRACP, FAHMS, FAA, FASCO, Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney, will present updated results from the Phase I study of STX-001, Strand’s intratumorally delivered, self-replicating mRNA therapy expressing IL-12. The STX-001 abstract was recognized among the Top 150 highest-scoring abstracts at SITC (Free SITC Whitepaper) 2026.
Abstract Title: Durable, Interferon-Associated Systemic Responses with STX-001, an LNP-Encapsulated IL-12-Expressing Self-Replicating mRNA, Used as Monotherapy in Advanced Solid Tumors in a Phase I/II Study
Abstract #: 823
Presentation Type: Oral presentation
Date and Time: Friday, November 6, 2026, 4:55-5:05 pm MT
Location: Phoenix Convention Center, West Building-300 Level, 301BC
STX-003: ASCENT-1 trial design
Trial principal investigator Melissa Johnson, MD, Chief Scientific Officer and Director of Lung Cancer Research at Sarah Cannon Research Institute, will present the trial-in-progress poster, which outlines the rationale and design for evaluating STX-003 – a systemically delivered, programmable self-replicating mRNA expressing IL-12 – initially as a monotherapy in patients with solid tumors, with potential subsequent evaluation in combination with pembrolizumab. Dosing of the first patients was announced on October 28, 2026.
Abstract Title: Phase I/II trial of STX-003, a systemically delivered programmable self-replicating mRNA expressing IL-12 ± pembrolizumab in solid tumors
Abstract #: 537
Presentation Type: Poster presentation
Date and Time: Friday, November 6, 2026, Poster Sessions
Location: Phoenix Convention Center, North Building-Lower Level, Exhibition Halls 4-6
Both abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC). Full details are available on the SITC (Free SITC Whitepaper) website.
(Press release, Strand Therapeutics, NOV 3, 2026, View Source [SID1234674117])